Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Dare Bioscience, Inc. (DARE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/27/2021 |
GN
| Daré Bioscience Announces Ovaprene®, a Novel Investigational Hormone-Free Contraceptive, Poster Presentation at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists |
| 03/30/2021 |
GN
| Daré Bioscience Reports Full Year 2020 Financial Results and Provides a Company Update |
| 03/24/2021 |
GN
| Daré Bioscience Announces Initiation of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder |
| 03/23/2021 |
GN
| Daré Bioscience to Host Full Year 2020 Financial Results and Company Update Conference Call and Webcast on March 30, 2021 |
| 03/02/2021 |
GN
| Daré Bioscience to Present at the H.C. Wainwright Global Life Sciences Conference |
| 02/25/2021 |
GN
| Daré Bioscience to Participate in Maxim Group's Late Stage Innovations in Women's Health Virtual Event |
| 02/16/2021 |
GN
| Daré Bioscience to Participate at the Women's Health Innovation Series: Contraception Innovation Summit to be held Virtually on February 23, 2021 |
| 12/07/2020 |
GN
| Daré Bioscience Announces Positive Topline Results From DARE-BVFREE, a Phase 3 Trial of DARE-BV1 in Patients Diagnosed with Bacterial Vaginosis |
| 11/12/2020 |
GN
| Daré Bioscience Reports Third Quarter 2020 Financial Results and Provides Company Update |
| 10/07/2020 |
GN
| Daré Bioscience to Present at the 2020 BIO Investor Forum Digital |
| 09/21/2020 |
GN
| Daré Bioscience Receives $0.9 million Under the Current Grant Supplement Award for Continued Development of its User-Controlled, Long Acting Reversible Contraceptive (DARE-LARC1) |
| 09/01/2020 |
GN
| Daré Bioscience and Avomeen Form Strategic Partnership to Accelerate the Development of Daré's Novel Pipeline of Women's Health Programs |
| 08/12/2020 |
GN
| Daré Bioscience Reports Second Quarter 2020 Financial Results and Provides Company Update |
| 06/24/2020 |
GN
| Daré Bioscience Announces Publication of a Peer-Reviewed Journal Article Supporting the Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Biology of Reproduction |
| 06/17/2020 |
GN
| Daré Bioscience Announces Initiation of Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis |
| 06/15/2020 |
GN
| Daré Bioscience Announces Receipt of $1.5 Million Under the Current Grant Supplement Award for Continued Development of User-Controlled Long Acting Reversible Contraceptive |
| 06/04/2020 |
GN
| Daré Bioscience Announces Participation in BIO Digital 2020 |
| 05/14/2020 |
GN
| Daré Bioscience Reports First Quarter 2020 Financial Results and Provides Company Update |
| 05/11/2020 |
GN
| Daré Bioscience and Health Decisions Form Strategic Partnership to Accelerate the Development of Daré's Novel Pipeline of Women's Health Programs |
| 05/07/2020 |
GN
| Daré Bioscience to Host First Quarter 2020 Financial Results and Company Update Conference Call and Webcast on May 14, 2020 |
| 04/28/2020 |
GN
| Daré Bioscience CEO to Participate in Maxim Group's Infectious Disease Virtual Conference |
| 04/23/2020 |
GN
| Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC |
| 04/01/2020 |
GN
| Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene® |
| 03/30/2020 |
GN
| Daré Bioscience Reports 2019 Financial Results and Provides a Company Update |
| 03/24/2020 |
GN
| Daré Bioscience to Host Fourth Quarter and Full-year 2019 Financial Results and Company Update Conference Call and Webcast on March 30, 2020 |
| 03/10/2020 |
GN
| Daré Bioscience Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis |
| 01/30/2020 |
GN
| Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule |
| 01/15/2020 |
GN
| Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update |
| 12/18/2019 |
GN
| Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study |
| 11/21/2019 |
GN
| Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform |
| 11/14/2019 |
GN
| Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update |
| 11/11/2019 |
GN
| Daré Bioscience Enters into Agreement to Acquire Microchips Biotech Including Its First-in-Class Wireless, User-Controlled Drug Delivery Platform |
| 10/31/2019 |
GN
| Daré Bioscience Announces Presentation of Two Posters at American Association of Pharmaceutical Scientists 2019 PharmSci 360 |
| 10/10/2019 |
GN
| Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo |
|
|
|